RESUMEN
Significant information on the dynamics of the plasma constituents in Hall effect thrusters can be obtained using minimally intrusive techniques, such as laser-induced fluorescence (LIF) diagnostics. Indeed, LIF provides an excellent tool to determine the ion velocity distribution function with high spatial resolution. Even in a steady-state operation, recording time-resolved maps of the velocity distribution is relevant due to persisting time-dependent features of the thruster discharge. One of the preeminent phenomena that render the ion velocity distribution to be time dependent is commonly attributed to the breathing mode, characterized by pronounced oscillations in the discharge current. The goal of this work is to propose a new technique for plasma dynamic studies based on LIF spectroscopy with phase-resolution during the breathing period. For this purpose, the Hilbert transform is used to define the instantaneous phase of oscillation of the thruster current. Ion velocity distribution modification over assigned phases of oscillation is measured simultaneously and in real-time thanks to a fully numerical analysis of the data.
RESUMEN
Refludan (lepirudin-rDNA for injection) is the first direct thrombin inhibitor approved by the United States FDA for anticoagulation to patients with heparin-induced thrombocytopenia (HIT). It was monitored by ecarin clotting time (ECT) assay in patients with HIT. Case histories and clotting parameters for three patients undergoing off-pump coronary artery revascularization procedure are discussed. The first patient received r-hirudin at a dose of 0.2 mg/kg intravenous (IV) bolus followed by 0.15 mg/kg/hour infusion. The second patient received 0.4 mg/kg IV bolus followed by infusion of 0.15 mg/kg/hour infusion. The third patient with renal failure received 0.2 mg/kg IV bolus followed by an infusion of 0.02 mg/kg/hour. Blood samples were drawn at baseline, 5 minutes post bolus and every 15 minutes during the coronary artery revascularization procedure. ECT was performed immediately on the citrated whole blood samples using the ECT cards in conjunction with the point-of-care, the thrombolytic assessment system (TAS) Analyzer (Pharmanetics, Raleigh, NC). The plasma samples were then analyzed for APTT and liquid ECT assay performed on a kinetic centrifugal analyzer (ACL 300 Plus). The ECT by cards was ideally maintained above 600 seconds during the surgical procedure. Additional boluses of Refludan were given as and when necessary (ECT < 600 sec) in order to maintain adequate anticoagulation. The calculated circulating concentrations of Refludan, following a bolus administration, based on the ECT cards, liquid ECT and APTT were 3.20 +/- 1.3, 3.51 +/- 1.35 and 2.02 +/- 1.19 microg/mL, respectively.